| Cash Flow | 2026-04-30 |
|---|---|
| Net loss | -4,023,106 |
| Amortization | 12,935 |
| Depreciation | 4,925 |
| Fixed asset, disposed | -2,741 |
| Represents the amount of gain on conversion of payables | 0 |
| Share-based payment arrangement, noncash expense | 449,755 |
| Represents the amount of shares issued for conversion of payables operating adjustment | 0 |
| Represents the amount of shares to be issued for services | 44,698 |
| Increase (decrease) in accounts payable and accrued liabilities | 198,759 |
| Increase (decrease) in due to related parties, current | 71,309 |
| Interest receivable | 2,171 |
| Taxes receivable | -3,037 |
| Increase (decrease) in employee related liabilities | -76,000 |
| Prepaid expenses | 59,546 |
| Increase (decrease) in security deposits | -12,317 |
| Amount of increase (decrease) in operating liabilities to be settled by shares | 44,700 |
| Net cash used in operating activities | -3,340,281 |
| Purchase of fixed assets | 34,829 |
| Change in convertible note receivables | 2 |
| Net cash used in investing activities | -34,831 |
| Represents the proceeds from receivable from issuance of private placement shares | 2,000,000 |
| Repayments on due to shareholders | 0 |
| Represents the amount of proceeds from shares to be issued for warrant inducements financing | 427,928 |
| Proceeds for warrants issued under the warrant inducement program | 564 |
| Proceeds from warrant exercises | 500 |
| Proceeds from issuance of private placement | 2,943,351 |
| Repayment of loan payable | 0 |
| Proceeds from offering costs paid for future offering | 42,177 |
| Represents the amount of proceeds received for warrants to be issued for warrant inducements | 543 |
| Represents the amount of proceeds received for shares to be issued for warrant inducements | 427,967 |
| Cash provided by (used in) financing activity, including discontinued operation | 5,843,030 |
| Cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation | 2,467,918 |
| Cash, cash equivalents and restricted cash at end of period | 4,834,120 |
| Cash, cash equivalents and restricted cash at end of period | 7,302,038 |
Conexeu Sciences Inc. (CNXU)
Conexeu Sciences Inc. (CNXU)